報價延遲最少15分鐘:2026/04/21 22:31 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.99 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.49/-0.92
|
|
企業價值
1.32B
|
| 資產負債 |
|
每股賬面淨值
3.19
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
75.13M
|
|
每股收益
0.17
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications. ABCL635, ABCL386, ABCL575, and ABCL635. |
